HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- (3- (4- benzoylpiperazin- 1- yl)- 2- (benzyloxycarbonylamino)- 3- oxopropyl)- 3,5- dimethylphenyl 4-methylbenzenesulfonate

a P2X7 receptor antagonist

Also Known As:

MRS 2540; MRS-2540; MRS2540

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzenesulfonates
        4-(3-(4-benzoylpiperazin-1-yl)-2-(benzyloxycarbonylamino)-3-oxopropyl)-3,5-dimethylphenyl 4-methylbenzenesulfonate: 2
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfonic Acids: 1605
      - Arylsulfonic Acids
        Arylsulfonates: 1
        Benzenesulfonates
        4-(3-(4-benzoylpiperazin-1-yl)-2-(benzyloxycarbonylamino)-3-oxopropyl)-3,5-dimethylphenyl 4-methylbenzenesulfonate: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - 4-(3-(4-benzoylpiperazin-1-yl)-2-(benzyloxycarbonylamino)-3-oxopropyl)-3,5-dimethylphenyl 4-methylbenzenesulfonate: 2

Experts

1.	Song, Jian-Tao: 1 article (01/2021)
2.	Tang, Yong: 1 article (01/2021)
3.	Ye, Shan-Shan: 1 article (01/2021)
4.	Argall, Arthur J: 1 article (09/2010)
5.	Hu, Huiling: 1 article (09/2010)
6.	Jacobson, Kenneth A: 1 article (09/2010)
7.	Kim, Yong-Chul: 1 article (09/2010)
8.	Laties, Alan M: 1 article (09/2010)
9.	Lee, Ga Eun: 1 article (09/2010)
10.	Lu, Wennan: 1 article (09/2010)

Related Diseases

1.	Ganglion Cysts (Ganglion) 09/01/2010 - "Ganglion cell death was inhibited by co-injection of the P2X(7) antagonists Brilliant Blue G and MRS 2540. "
2.	Glaucoma 01/01/2021 - "Several agonists and antagonists of ATP receptors and adenosine receptors (ARs) have been developed for the potential treatment of glaucoma, DR and AMD: antagonists of P2X7 receptor (P2X7R) (BBG, MRS2540) prevent ATP-induced neuronal apoptosis in glaucoma, DR, and AMD; A1 receptor (A1R) agonists (INO-8875) lower intraocular pressure in glaucoma; A2A receptor (A2AR) agonists (CGS21680) or antagonists (SCH58261, ZM241385) reduce neuroinflammation in glaucoma, DR, and AMD; A3 receptor (A3R) agonists (2-Cl-lB-MECA, MRS3558) protect retinal ganglion cells (RGCs) from apoptosis in glaucoma."
3.	Neuroinflammatory Diseases 01/01/2021 - "Several agonists and antagonists of ATP receptors and adenosine receptors (ARs) have been developed for the potential treatment of glaucoma, DR and AMD: antagonists of P2X7 receptor (P2X7R) (BBG, MRS2540) prevent ATP-induced neuronal apoptosis in glaucoma, DR, and AMD; A1 receptor (A1R) agonists (INO-8875) lower intraocular pressure in glaucoma; A2A receptor (A2AR) agonists (CGS21680) or antagonists (SCH58261, ZM241385) reduce neuroinflammation in glaucoma, DR, and AMD; A3 receptor (A3R) agonists (2-Cl-lB-MECA, MRS3558) protect retinal ganglion cells (RGCs) from apoptosis in glaucoma."

Related Drugs and Biologics

1.	Purinergic P2X7 Receptors
2.	Purinergic P2 Receptors (ADP Receptor)
3.	Purinergic P1 Receptors (Adenosine Receptor)
4.	Adenosine Triphosphate (ATP)
5.	5- amino- 7- (2- phenylethyl)- 2- (2- furyl)pyrazolo(4,3- e)- 1,2,4- triazolo(1,5- c)pyrimidine
6.	ZM 241385 (ZM241385)
7.	2- (4- (2- carboxyethyl)phenethylamino)- 5'- N- ethylcarboxamidoadenosine
8.	coomassie Brilliant Blue